Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Erasmus University Medical Center Rotterdam has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 examiners and 5 art units, so no shared examiner or art-unit concentration appears in the supplied data.
LEWOCZKO, EVAN MICHAEL is the busiest examiner, with 1 pending matter. Each response should be managed as an individual examination track, with portfolio-level coordination focused on consistency rather than assignment consolidation.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
| ORWIG, KEVIN S | 1 | 25.5% | +40.1% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 2d overdue |
| 18868678 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | LEWOCZKO, EVAN MICHAEL | — |
| 18734779 | REAGENTS, METHODS AND KITS FOR DIAGNOSING PRIMARY IMMUNODEFICIENCIES | GABEL, GAILENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 2d overdue |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | BERTOGLIO, VALARIE E | 5d |
| 18734779 | REAGENTS, METHODS AND KITS FOR DIAGNOSING PRIMARY IMMUNODEFICIENCIES | GABEL, GAILENE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1678 | 1 |
| 3991 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18868678 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | LEWOCZKO, EVAN MICHAEL | 1612 | §103§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18734779 | REAGENTS, METHODS AND KITS FOR DIAGNOSING PRIMARY IMMUNODEFICIENCIES | GABEL, GAILENE | 1678 | §102§103§112Other | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | ORWIG, KEVIN S | 3991 | §103§112Other | Non-Final OA | 2d overdue | Pending | Sep 14, 2023 |
| 17833506 | METHOD FOR CULTURING MYOGENIC CELLS, CULTURES OBTAINED THEREFROM, SCREENING METHODS, AND CELL CULTURE MEDIUM | BERTOGLIO, VALARIE E | 1632 | §112 | Final Rejection | 5d | Pending | Jun 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialErasmus University Medical Center Rotterdam has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Evan Michael Lewoczko has the most, with 1 of Erasmus University Medical Center Rotterdam's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
